利拉鲁肽与二甲双胍合用对超重的2型糖尿病患者代谢指标的影响  

Clinical efficacy of liraglutide combined with metformin in the treatment of obesity type 2 diabetes

作　　者：李珊珊[1] 孙剑[2] 

机构地区：[1]贵阳中医学院,贵州贵阳550003 [2]内蒙古包头医学院第二附属医院内分泌科,内蒙古包头014030

出　　处：《中国医药科学》2015年第17期96-98,共3页China Medicine And Pharmacy

摘　　要：目的观察利拉鲁肽与二甲双胍合用对超重的2型糖尿病患者代谢指标的影响。方法选取40例经二甲双胍口服治疗3个月但血糖仍未达标的合并体重超重的2型糖尿病患者,给予联合利拉鲁肽治疗12周,检测并分析血糖及其他相关指标变化。结果 12周后,患者腹围较前下降,但差异无统计学意义(P>0.05);患者体重、体重指数、空腹血糖、胰岛素抵抗指数HOMA-IR、糖化血红蛋白、低密度脂蛋白胆固醇水平较前下降,差异具有统计学意义(P<0.05);胰岛β细胞功能指数HOMA-β升高,差异具有统计学意义(P<0.05)。联合治疗期间无严重低血糖事件发生。结论对于合并超重的2型糖尿病患者,利拉鲁肽联合二甲双胍治疗安全有效,且对体重指数、胰岛素抵抗指数HOMA-IR、胰岛β细胞功能指数HOMA-β、糖化血红蛋白、血脂等代谢指标均有明显改善作用。Objective To study the therapeutic effects of the combination of Liraglutide and Metformin on obesity patients with type 2 diabetes（T2DM）. Methods 40 obesity patients with type 2 diabetes whose blood glucose were not well controlled by taking oral metformin 3 months,given liraglutide and metformin therapy for 3 months.To explore abdomen circumference,the levels of fasting blood glucose,2h postprandial blood glucose,glycosylated hemoglobin,blood fat after treatment for 12 weeks. Results After 3 months treatment,Hb A1 c,FPG,2 h PG,HOMA-IR,low density lipoprotein cholesterol and BMI were reduced（P〈0.05）.HOMA-β were increased（P〈0.05）.Minority patients had nausea and discomfort of gastrointestinal symptoms within endurance. Conclusion Combination of liraglutide and metformin can significantly decrease blood glucose,reduce weight gain and serum lipid,improve insulin function which is a safe and effective therapy strategy for fatty type 2 diabetic patients.

关 键 词：利拉鲁肽 二甲双胍 2型糖尿病 

分 类 号：R587.1[医药卫生—内分泌]